Please login to the form below

Not currently logged in
Email:
Password:

Alkermes

This page shows the latest Alkermes news and features for those working in and with pharma, biotech and healthcare.

Tecfidera successor’s side-effect profile boosts Biogen

Tecfidera successor’s side-effect profile boosts Biogen

Vumerity is being developed by Biogen in partnership with Alkermes, and is already filed with the FDA, with a decision due in Q4 of 2019.

Latest news

  • Biogen trumpets safety data for Tecfidera follow-up Biogen trumpets safety data for Tecfidera follow-up

    Alkermes-partnered diroximel fumarate (formerly BIIB098) – which has the proposed trade name Vumerity – is due for an FDA verdict before the end of the year, mere months before Biogen is due

  • Spinraza keeps Biogen afloat as Tecfidra stalls Spinraza keeps Biogen afloat as Tecfidra stalls

    Biogen and partner Alkermes are also awaiting an FDA verdict on their new oral multiple sclerosis candidate, BIIB098, a follow-up to Tecfidra.

  • FDA starts review of Biogen’s Tecfidera follow-up for MS FDA starts review of Biogen’s Tecfidera follow-up for MS

    Biogen and partner Alkermes could get an FDA verdict on their new oral multiple sclerosis therapy BIIB098 by the end of the year after the agency formally started its review process. ... Alkermes is entitled to a mid-teen royalty on worldwide sales of

  • Biogen files Tecfidera follow-up in the US Biogen files Tecfidera follow-up in the US

    So far, Alkermes says it has seen discontinuation rates with the new drug at below 1%, well below the 6%-7% reported in trials of Tecfidera. ... Alkermes pocketed a $50m milestone payment from Biogen on the strength of preliminary comparative

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    studies, with Alkermes’ dossier relying on a third positive trial to prop up the overall data set. ... Alkermes was hoping that the massive unmet need in patients with MDD would help sway the FDA.

More from news
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Srdjan Stankovic joins Acadia Pharmaceuticals Srdjan Stankovic joins Acadia Pharmaceuticals

    He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... He joins the firm from  Alkermes,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics